Barclays Maintains Overweight on Tenet Healthcare, Lowers Price Target to $238

Benzinga Newsdesk www.benzinga.com Negative 73.6%

Neg 73.6% Neu 0% Pos 0%

Barclays analyst Andrew Mok maintains Tenet Healthcare (NYSE:THC) with a Overweight and lowers the price target from $257 to $238.